Logo

LFVN

LifeVantage Corporation

LFVN

LifeVantage Corporation • NASDAQ
$6.87 ▲ 1.63% (+0.11)
Market Cap $87.23 M
52w High $27.38
52w Low $5.98
Dividend Yield 0.17%
P/E 8.81
Volume 47.17K
Outstanding Shares 12.70M

Income Statement

Period Revenue Operating Expense Net Income Net Profit Margin Earnings Per Share EBITDA
Q1-2026 $58.44M ▲ $43.274M ▲ $3.47M ▲ 5.938% ▲ $0.28 ▲ $4.983M ▲
Q4-2025 $55.114M ▼ $41.901M ▼ $1.959M ▼ 3.554% ▼ $0.16 ▼ $2.898M ▼
Q3-2025 $58.44M ▼ $43.274M ▼ $3.47M ▲ 5.938% ▲ $0.28 ▲ $4.856M ▲
Q2-2025 $67.762M ▲ $51.139M ▲ $2.55M ▲ 3.763% ▼ $0.21 ▲ $4.234M ▲
Q1-2025 $47.214M $35.153M $1.826M 3.867% $0.15 $3.367M

Balance Statement

Period Cash & Short-term Total Assets Total Liabilities Total Equity
Q1-2026 $13.091M ▼ $61.579M ▼ $28.422M ▼ $33.157M ▲
Q4-2025 $21.595M $68.527M $38.638M $29.889M
Q3-2025 $21.595M ▲ $68.527M ▲ $38.638M ▲ $29.889M ▲
Q2-2025 $14.596M $61.46M $33.763M $27.697M
Q1-2025 $14.596M $61.46M $33.763M $27.697M

Cash Flow Statement

Period Net Income Cash From Operations Cash From Investing Cash From Financing Net Change Free Cash Flow
Q1-2026 $2.155M ▲ $-2.305M ▼ $-439K ▼ $-4.297M ▼ $-7.11M ▼ $-2.744M ▼
Q4-2025 $1.959M ▼ $1.034M ▼ $-199K ▲ $-3.243M ▼ $-2.268M ▼ $835K ▼
Q3-2025 $3.47M ▲ $2.228M ▼ $-331K ▲ $-1.127M ▲ $874K ▼ $1.897M ▼
Q2-2025 $2.55M ▲ $9.199M ▲ $-492K ▼ $-1.4M ▲ $6.999M ▲ $8.707M ▲
Q1-2025 $1.826M $-583K $-345K $-1.828M $-2.29M $-932K

Revenue by Products

Product Q1-2013Q2-2013Q3-2013Q1-2026
LifeVantage TrueScience Skin Care Regimen
LifeVantage TrueScience Skin Care Regimen
 $0 ▲$0 ▲$0 ▲$10.00M ▲
Product and Service Other
Product and Service Other
 $0 ▲$0 ▲$0 ▲$0 ▲
Protandim
Protandim
 $0 ▲$0 ▲$0 ▲$20.00M ▲
U S
U S
 $30.00M ▲$30.00M ▲$30.00M ▲$0 ▼

Five-Year Company Overview

Income Statement

Income Statement Revenue over the past several years has been fairly stable, with a slight upward tilt most recently rather than strong, consistent growth. Gross margins look healthy for a consumer wellness company, but operating and net profits are thin, hovering close to break-even in several years. That means the business is functioning, but with limited cushion: small swings in sales, distributor activity, or costs can move results from profit to loss. Earnings per share have also been quite uneven, suggesting that profitability is not yet on a smooth, predictable trajectory.

Balance Sheet

Balance Sheet The balance sheet appears relatively conservative and steady. Total assets and equity have been fairly stable over time, which indicates no major expansion but also no obvious balance sheet stress. Cash levels look consistent, not overly large but seemingly sufficient for the current scale of operations. Debt is present but modest, so financial leverage does not appear extreme. Overall, the company seems to be run with a restrained capital structure rather than an aggressive, debt-fueled approach.

Cash Flow

Cash Flow Cash generation is a relative bright spot: operating cash flow has been consistently positive, even while accounting profits were only modest. Free cash flow has generally stayed in positive territory, helped by very light capital spending needs. This pattern suggests the business model is cash-generative and not very capital intensive, which gives management some flexibility for things like marketing, distributor incentives, or small acquisitions, even if reported earnings remain thin.

Competitive Edge

Competitive Edge LifeVantage competes in a crowded supplements and wellness market but has carved out a distinct narrative around “activation” and nutrigenomics. Its moat is a blend of patented flagship products, a strong brand story around cellular pathways, and a direct-selling (MLM) network that can create loyal customers and distributors. That said, the moat has vulnerabilities: scientific claims face mixed external validation, MLM models draw public and regulatory scrutiny, and the broader category is highly competitive with many lookalike offerings and fast-moving trends. The position is differentiated, but not unassailable.

Innovation and R&D

Innovation and R&D Innovation centers on the idea of activating specific biological pathways (Nrf2, NRF1, NAD, GLP-1, gut peptides) and then extending that concept across nutrition and skincare. The company is actively refreshing its lineup with systems for weight management and gut health, and it is willing to use acquisitions to accelerate that pipeline. However, the innovation strategy leans heavily on marketing and early-stage or company-sponsored studies. The key uncertainty is how much of the science will be strongly confirmed by independent, peer-reviewed work and how that, in turn, will influence long-term customer trust and repeat use.

Summary

LifeVantage looks like a small, steady, but low-margin wellness business built around a distinctive science-focused story and a direct-selling model. Financially, it has stable revenue, reasonable gross margins, thin but improving profitability, and consistently positive cash flow supported by a light capital structure and modest debt. Strategically, it benefits from a clear brand niche in nutrigenomics and an expanding product ecosystem in weight, gut, and skin health, but it operates under ongoing debate about the real-world impact of its products and the resilience of its MLM distribution. Future outcomes will depend heavily on stronger clinical validation, successful international rollouts, and the company’s ability to keep its distributor base engaged while navigating a very competitive and fast-changing wellness landscape.

NEWS

November 12, 2025 · 8:00 AM UTC

New Study Finds LifeVantage's P84 Positively Impacts Gut Peptide Production, Activating Key Elements for Comprehensive Gut Health

Read more

November 4, 2025 · 4:06 PM UTC

LifeVantage Declares Quarterly Dividend

Read more

November 4, 2025 · 4:05 PM UTC

LifeVantage Announces Financial Results for the First Quarter of Fiscal 2026

Read more

October 28, 2025 · 8:00 AM UTC

LifeVantage Empowers Consultants to “Love Life & Drive” at Momentum Academy 2025

Read more

October 21, 2025 · 4:05 PM UTC

LifeVantage to Announce First Quarter Fiscal Year 2026 Results on November 4, 2025

Read more